Michelle Kameda-Smith to Medulloblastoma
This is a "connection" page, showing publications Michelle Kameda-Smith has written about Medulloblastoma.
Connection Strength
2.873
-
National multicentered retrospective review of clinical and intraoperative factors associated with the development of cerebellar mutism after pediatric posterior fossa tumor resection. Childs Nerv Syst. 2024 May; 40(5):1339-1347.
Score: 0.614
-
Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma. Nat Commun. 2022 12 06; 13(1):7506.
Score: 0.568
-
Pediatric medulloblastoma in the molecular era: what are the surgical implications? Cancer Metastasis Rev. 2020 03; 39(1):235-243.
Score: 0.469
-
Salvage Therapy for Childhood Medulloblastoma: A Single Center Experience. Can J Neurol Sci. 2019 07; 46(4):403-414.
Score: 0.447
-
Early rhombic lip Protogenin+ve stem cells in a human-specific neurovascular niche initiate and maintain group 3 medulloblastoma. Cell. 2024 Aug 22; 187(17):4733-4750.e26.
Score: 0.158
-
An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma. J Neurooncol. 2023 Jul; 163(3):635-645.
Score: 0.147
-
Wnt activation as a therapeutic strategy in medulloblastoma. Nat Commun. 2020 08 28; 11(1):4323.
Score: 0.121
-
Salvage therapy for progressive, treatment-refractory or recurrent pediatric medulloblastoma: a systematic review protocol. Syst Rev. 2020 03 04; 9(1):47.
Score: 0.117
-
BMI1 is a therapeutic target in recurrent medulloblastoma. Oncogene. 2019 03; 38(10):1702-1716.
Score: 0.107
-
Convergence of BMI1 and CHD7 on ERK Signaling in Medulloblastoma. Cell Rep. 2017 Dec 05; 21(10):2772-2784.
Score: 0.100
-
Analysis of surgical and MRI factors associated with cerebellar mutism. J Neurooncol. 2017 Jul; 133(3):539-552.
Score: 0.024